Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EBIT (2016 - 2025)

Acro Biomedical has reported EBIT over the past 10 years, most recently at -$16377.0 for Q4 2025.

  • Quarterly results put EBIT at -$16377.0 for Q4 2025, down 72.97% from a year ago — trailing twelve months through Dec 2025 was -$154024.0 (down 305.77% YoY), and the annual figure for FY2025 was -$154024.0, down 305.77%.
  • EBIT for Q4 2025 was -$16377.0 at Acro Biomedical, up from -$115099.0 in the prior quarter.
  • Over the last five years, EBIT for ACBM hit a ceiling of $6.9 million in Q4 2023 and a floor of -$4.0 million in Q3 2022.
  • Median EBIT over the past 5 years was -$86045.0 (2021), compared with a mean of -$976392.6.
  • Biggest five-year swings in EBIT: skyrocketed 2962.54% in 2021 and later crashed 6793.35% in 2022.
  • Acro Biomedical's EBIT stood at $2.2 million in 2021, then crashed by 276.85% to -$3.9 million in 2022, then skyrocketed by 276.35% to $6.9 million in 2023, then crashed by 100.14% to -$9468.0 in 2024, then plummeted by 72.97% to -$16377.0 in 2025.
  • The last three reported values for EBIT were -$16377.0 (Q4 2025), -$115099.0 (Q3 2025), and -$13614.0 (Q2 2025) per Business Quant data.